Market Snapshot

S&P Futures
Dow Futures
NASDAQ Futures

Tiziana Life Sciences Inc. (TLSA) stock rises in the current market trading. Why is it so?

Related Topics

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Tiziana Life Sciences Inc. (TLSA) stock surges by 9.06% in the current market trading session after TLSA stock announced the positive progress of the Foralumab program, which is designed to counter COVID-19 and secondary progressive multiple sclerosis. Tiziana Life Sciences plc is a dual-listed biotechnology firm specializing in the research and development of novel molecules to fight diseases like cancer, inflammation, and other infectious diseases in humans.

What is happening?

TLSA stock has declared that the US Food and Drug Administration (FDA) has approved the use of Foralumab, a completely human anti-CD3 monoclonal antibody, in a secondary progressive multiple sclerosis (SPMS) patient at Harvard University’s Brigham and Women’s Hospital (BWH), Boston, MA. This is the first time a nasally administered antibody will be provided to a patient with SPMS, and it will be handled under an Individual Patient Expanded Access IND. The treatment will begin in the second quarter of 2021 and will last for six months.

To test microglial imaging, researchers at BWH will perform comprehensive routine protection, neurological, imaging, and PET studies on this patient. Normal investigations at the BWH will include the modification of immunological and neurodegenerative indicators.

Previous record of Phase 1 Trial

Tiziana previously completed a Phase 1 trial in healthy subjects with a single-site, double-blind, placebo-controlled, multiple ascending dose (MAD) one time in a day dosing for 5 days with nasally administered Foralumab. At doses up to 250 mg, the treatment was well received, with no drug-related adverse effects recorded. Professor Howard of BHW invented nasal foralumab.


TLSA had previously confirmed that the Clinical Trial of Nasal Administration with Foralumab in COVID-19 patients in Brazil had yielded promising results. Nasally administered Foralumab at 100 mg/day for a 10-day treatment period was found to be well-tolerated, with no serious adverse effects reported. Clinical evidence suggested that the procedure reduced lung inflammation significantly. This indicates that the recent development is expected to raise the progress graph for TLSA.

Leave a Comment

Your email address will not be published. Required fields are marked *

Sign up for our FREE Newsletter and get:
Sign up for our FREE Newsletter and get:


Latest Posts